Artwork

Innhold levert av Ira Pastor. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Ira Pastor eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

Michael Demurjian - CEO, Aspargo Labs - Improving Patient Experience With Novel Formulations & Technology

44:11
 
Del
 

Manage episode 451361312 series 2835025
Innhold levert av Ira Pastor. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Ira Pastor eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Send us a text

Michael Demurjian is CEO And Chairman of Aspargo Labs ( https://aspargolabs.com/ ), which he co-founded in 2019, which is a distinguished pharmaceutical and med-tech company committed to developing innovative oral spray formulations and drug delivery systems.
Mr. Demurjian brings extensive experience across finance, manufacturing, sales & marketing, logistics, and general management. He has experience in taking companies public, raising funds in public and private markets with both retail and institutional investors.
Prior to Aspargo Labs, Mr. Demurjian served as COO, CFO and member of the Board of Directors of Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have tolerable toxicity profiles. At Tyme, Mr. Demurjian was instrumental in raising over 50 million dollars and obtaining a public listing on NASDAQ. He also served as CEO of Luminant Biosciences, an oncology research company studying metabolic pathways to destroying cancer cells.
Throughout his career, Mr. Demurjian has successfully completed strategic transactions with G.E., Stryker, Black & Decker Corp., and Crane Cams.
Mr. Demurjian currently sits on the Board of Directors of the Susan G. Komen Foundation, the NYU board of advisors and has served in the past on the Board of Directors of Luminant Bio., Mikronite Tech & KCC.
#Aspargo #MichaelDemurjian #DrugFormulation #PatientCompliance #LiquidOralSuspensions #Bioavailability #Pharmacokinetics #Pharamcodynamics #Pharmacology #Adherence #Sildenafil #Dimenhydrante #Statins #Metformin #PotassiumIodide #Antiemetics #Dysphagia #MeteredDose #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research

Support the show

  continue reading

568 episoder

Artwork
iconDel
 
Manage episode 451361312 series 2835025
Innhold levert av Ira Pastor. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Ira Pastor eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Send us a text

Michael Demurjian is CEO And Chairman of Aspargo Labs ( https://aspargolabs.com/ ), which he co-founded in 2019, which is a distinguished pharmaceutical and med-tech company committed to developing innovative oral spray formulations and drug delivery systems.
Mr. Demurjian brings extensive experience across finance, manufacturing, sales & marketing, logistics, and general management. He has experience in taking companies public, raising funds in public and private markets with both retail and institutional investors.
Prior to Aspargo Labs, Mr. Demurjian served as COO, CFO and member of the Board of Directors of Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have tolerable toxicity profiles. At Tyme, Mr. Demurjian was instrumental in raising over 50 million dollars and obtaining a public listing on NASDAQ. He also served as CEO of Luminant Biosciences, an oncology research company studying metabolic pathways to destroying cancer cells.
Throughout his career, Mr. Demurjian has successfully completed strategic transactions with G.E., Stryker, Black & Decker Corp., and Crane Cams.
Mr. Demurjian currently sits on the Board of Directors of the Susan G. Komen Foundation, the NYU board of advisors and has served in the past on the Board of Directors of Luminant Bio., Mikronite Tech & KCC.
#Aspargo #MichaelDemurjian #DrugFormulation #PatientCompliance #LiquidOralSuspensions #Bioavailability #Pharmacokinetics #Pharamcodynamics #Pharmacology #Adherence #Sildenafil #Dimenhydrante #Statins #Metformin #PotassiumIodide #Antiemetics #Dysphagia #MeteredDose #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research

Support the show

  continue reading

568 episoder

所有剧集

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2024 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett